EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO
EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD Achieving All Primary and Secondary Endpoints GlobeNewswireWatertown biotech shares surge nearly 200% on new drug data -…